Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

Hepatology

Volumn 51, Issue 2, 2010, Pages 615-620

  Lammert, Craig ^a   Bjornsson, Einar ^b   Niklasson, Anna ^b   Chalasani, Naga ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ARTICLE; DRUG FATALITY; JAUNDICE; LIVER FAILURE; LIVER METABOLISM; LIVER TOXICITY; LIVER TRANSPLANTATION; PRIORITY JOURNAL; TOXIC HEPATITIS;

ADMINISTRATION, ORAL; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; PRESCRIPTION DRUGS; RISK FACTORS;

EID: 75449112589     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23317     Document Type: Article

References (23)

1. Gibson GG, Skett P. Introduction to Drug Metabolism. 3rd ed. Cheltenham, UK: Nelson Thornes, 2001.
2. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92.
3. Abboud G. Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30: 277-294.
4. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-739.
5. Walgreen JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-361.
6. Watkins PB. The role of cytochrome P450s in drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. 1st ed. New York: Marcel Dekker, Inc.; 2003:15-34.
7. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the danger hypothesis and innate immune system. Chem Res Toxicol 1999;12:387-395.
8. Tang W, Stearns RA, Bandeira SM, Zhang Y, Raab C, Braun MP, et al. Studies on cytochrome P-450 mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 1999;27:365-372.
9. Lewis JH, Larrey D, Olsson R, Lee WM, Frison L, Keisu M. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther 2008;46:327-339.
10. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-195.
11. Drug Topics. Top 200 brand drugs by units in 2005. Available at: http://www.drugtopics.com/drugtopics/data/articlestandard//drugtopics/102006/ 311293/article.pdf. Accessed November 2, 2007.
12. Drug Topics. Top 200 generic drugs by units in 2005. Available at: http://www.drugtopics.com/drugtopics/data/articlestandard//drugtopics/102006/ 311294/article.pdf. Accessed November 2, 2007.
13. DRUGDEX system. Available at: http://www.micromedex.com/products/drugdex/ . Accessed November 2, 2007.
14. Dollery C, ed. Therapeutic Drugs. 2nd ed. Edinburgh, UK: Churchill Livingstone; 1999.
15. McEnvoy GK. AHFS Drug Information. London: Transatlantic Publishers; 2006.
16. FASS-the Swedish Medicines Information Engine. Available at http://www.fass.se. Accessed February 1, 2008.
17. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver disease: search for signals.HEPATOLOGY 2008;47:2003-2009.
18. Physician Desk Reference. Available at: http://www.pdr.net/login/Login. aspx. Accessed November 2, 2007.
19. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23:16-24.
20. Einarsdottir S, Björnsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008;20:1049.
21. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-I concept. Curr Opin Allergy Clin Immunol 2002;2:301-305.
22. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. HEPATOLOGY 2006;44:778-787.
23. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender. HEPATOLOGY 2009;49:2001-2009.